View ValuationPacific Edge 将来の成長Future 基準チェック /26Pacific Edge利益と収益がそれぞれ年間64.8%と41.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-7.9% 69.8%なると予測されています。主要情報64.8%収益成長率69.77%EPS成長率Biotechs 収益成長34.0%収益成長率41.3%将来の株主資本利益率-7.86%アナリストカバレッジLow最終更新日25 May 2026今後の成長に関する最新情報Breakeven Date Change • May 12Forecast to breakeven in 2028The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 8.0% per year to 2027. The company is expected to make a profit of NZ$6.80m in 2028. Average annual earnings growth of 55% is required to achieve expected profit on schedule.Breakeven Date Change • May 21No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$28.8m in 2027. New consensus forecast suggests the company will make a loss of NZ$15.4m in 2027.Breakeven Date Change • Nov 24No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.62m in 2023. New consensus forecast suggests the company will make a loss of NZ$1.85m in 2024.Breakeven Date Change • Sep 28Forecast to breakeven in 2023The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$4.58m in 2023. Average annual earnings growth of 94% is required to achieve expected profit on schedule.すべての更新を表示Recent updatesお知らせ • Jul 02Pacific Edge Limited, Annual General Meeting, Aug 20, 2026Pacific Edge Limited, Annual General Meeting, Aug 20, 2026. Location: auckland New ZealandReported Earnings • May 26Full year 2026 earnings released: NZ$38.00 loss per share (vs NZ$0.037 loss in FY 2025)Full year 2026 results: NZ$38.00 loss per share (further deteriorated from NZ$0.037 loss in FY 2025). Revenue: NZ$13.6m (down 40% from FY 2025). Net loss: NZ$35.8m (loss widened 20% from FY 2025). Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 4.1% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 179 percentage points per year, which is a significant difference in performance.New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (NZ$18m net loss in 2 years).お知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026Breakeven Date Change • May 12Forecast to breakeven in 2028The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 8.0% per year to 2027. The company is expected to make a profit of NZ$6.80m in 2028. Average annual earnings growth of 55% is required to achieve expected profit on schedule.New Risk • Mar 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$145.8m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$145.8m market cap, or US$99.9m).New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding).Reported Earnings • Nov 27First half 2026 earnings released: NZ$0.022 loss per share (vs NZ$0.018 loss in 1H 2025)First half 2026 results: NZ$0.022 loss per share (further deteriorated from NZ$0.018 loss in 1H 2025). Revenue: NZ$6.84m (down 40% from 1H 2025). Net loss: NZ$19.1m (loss widened 32% from 1H 2025). Revenue is expected to decline by 2.8% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Australia are expected to grow by 7.6%. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.New Risk • Nov 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$147.4m market cap, or US$95.3m).New Risk • Nov 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.9m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$4.9m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$150.9m market cap, or US$98.6m).お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$11m net loss in 3 years). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$122.8m market cap, or US$79.7m).お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealandお知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct ListingReported Earnings • Jun 01Full year 2025 earnings released: NZ$0.037 loss per share (vs NZ$0.036 loss in FY 2024)Full year 2025 results: NZ$0.037 loss per share (further deteriorated from NZ$0.036 loss in FY 2024). Revenue: NZ$24.7m (down 2.2% from FY 2024). Net loss: NZ$29.9m (loss widened 1.4% from FY 2024). Revenue is expected to decline by 25% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Australia are expected to grow by 8.6%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.お知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listingお知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025New Risk • Jan 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: NZ$29m Forecast net loss in 2 years: NZ$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$23m net loss in 2 years). Market cap is less than US$100m (AU$44.0m market cap, or US$27.0m).Reported Earnings • Nov 30First half 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.019 loss in 1H 2024)First half 2025 results: NZ$0.018 loss per share (improved from NZ$0.019 loss in 1H 2024). Revenue: NZ$11.3m (down 19% from 1H 2024). Net loss: NZ$14.5m (loss narrowed 4.9% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024Reported Earnings • May 21Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)Full year 2024 results: NZ$0.036 loss per share (further deteriorated from NZ$0.033 loss in FY 2023). Revenue: NZ$28.7m (up 36% from FY 2023). Net loss: NZ$29.5m (loss widened 9.5% from FY 2023).Breakeven Date Change • May 21No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$28.8m in 2027. New consensus forecast suggests the company will make a loss of NZ$15.4m in 2027.お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Anna Stove was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.Reported Earnings • Nov 24First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)First half 2024 results: NZ$0.019 loss per share (further deteriorated from NZ$0.013 loss in 1H 2023). Revenue: NZ$14.0m (up 47% from 1H 2023). Net loss: NZ$15.3m (loss widened 44% from 1H 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in Australia.お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023Recent Insider Transactions • Sep 21Independent Non-Executive Director recently bought AU$2.8m worth of stockOn the 15th of September, Anatole G. Masfen bought around 9m shares on-market at roughly AU$0.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$2.9m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Aug 04Key Executive recently bought AU$50k worth of stockOn the 2nd of August, Chris Gallaher bought around 398k shares on-market at roughly AU$0.13 per share. This transaction amounted to 66% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Chris' only on-market trade for the last 12 months.お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$80.1m (US$53.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (AU$80.1m market cap, or US$53.4m).Reported Earnings • May 26Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: NZ$0.033 loss per share (further deteriorated from NZ$0.026 loss in FY 2022). Revenue: NZ$23.8m (up 81% from FY 2022). Net loss: NZ$27.0m (loss widened 36% from FY 2022). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia.Reported Earnings • Nov 28First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)First half 2023 results: NZ$0.013 loss per share (further deteriorated from NZ$0.012 loss in 1H 2022). Revenue: NZ$9.47m (up 55% from 1H 2022). Net loss: NZ$10.6m (loss widened 18% from 1H 2022). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Australia.Reported Earnings • May 27Full year 2022 earnings released: NZ$0.026 loss per share (vs NZ$0.02 loss in FY 2021)Full year 2022 results: NZ$0.026 loss per share (down from NZ$0.02 loss in FY 2021). Revenue: NZ$13.7m (up 53% from FY 2021). Net loss: NZ$19.8m (loss widened 39% from FY 2021). Over the next year, revenue is forecast to grow 60%, compared to a 71% growth forecast for the pharmaceuticals industry in Australia.Buying Opportunity • May 27Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be AU$0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 93% over the last year. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 46% per annum. Earnings is forecast to decline by 3.7% per annum over the same time period.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Sarah Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Sarah Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 26First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: NZ$0.012 loss per share (down from NZ$0.01 loss in 1H 2021). Revenue: NZ$6.13m (up 71% from 1H 2021). Net loss: NZ$8.99m (loss widened 27% from 1H 2021). Revenue exceeded analyst estimates by 3.6%. Over the next year, revenue is forecast to grow 85%, compared to a 176% growth forecast for the industry in Australia.Breakeven Date Change • Nov 24No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.62m in 2023. New consensus forecast suggests the company will make a loss of NZ$1.85m in 2024.Breakeven Date Change • Sep 28Forecast to breakeven in 2023The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$4.58m in 2023. Average annual earnings growth of 94% is required to achieve expected profit on schedule.業績と収益の成長予測ASX:PEB - アナリストの将来予測と過去の財務データ ( )NZD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202830-15N/A-1613/31/202719-28N/A-2913/31/202613-36-32-32N/A12/31/202516-35-32-32N/A9/30/202518-35-32-31N/A6/30/202520-32-29-28N/A3/31/202523-30-26-25N/A12/31/202423-29-25-24N/A9/30/202423-29-24-23N/A6/30/202424-29-26-24N/A3/31/202425-30-27-26N/A12/31/202325-31-28-26N/A9/30/202326-32-29-27N/A6/30/202323-29-29-26N/A3/31/202321-27-28-26N/A12/31/202219-24-27-24N/A9/30/202216-21-25-23N/A6/30/202215-21-22-20N/A3/31/202213-20-19-18N/A12/31/202112-18-17-16N/A9/30/202112-16-15-15N/A6/30/202110-15-15-14N/A3/31/20219-14-14-14N/A12/31/20207-15-15-15N/A9/30/20206-17-16-16N/A6/30/20205-18-16-16N/A3/31/20205-19-16-15N/A12/31/20195-19N/A-16N/A9/30/20195-19N/A-16N/A6/30/20195-18N/A-17N/A3/31/20195-18N/A-18N/A12/31/20185-18N/A-17N/A9/30/20185-18N/A-17N/A6/30/20185-19N/A-17N/A3/31/20185-20N/A-18N/A12/31/20174-20N/A-19N/A9/30/20173-21N/A-19N/A6/30/20174-22N/A-18N/A3/31/20174-23N/A-18N/A12/31/20166-21N/A-18N/A9/30/20168-20N/A-17N/A6/30/20167-18N/A-17N/A3/31/20166-16N/A-17N/A12/31/20155-15N/A-16N/A9/30/20154-15N/A-16N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PEB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PEB今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: PEB今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PEBの収益 ( 41.3% ) Australian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。高い収益成長: PEBの収益 ( 41.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PEB 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/16 13:55終値2026/07/16 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pacific Edge Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関null nullBrookline Capital MarketsMaxim JacobsEdison Investment ResearchBenjamin CrozierForsyth Barr Group Ltd.3 その他のアナリストを表示
Breakeven Date Change • May 12Forecast to breakeven in 2028The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 8.0% per year to 2027. The company is expected to make a profit of NZ$6.80m in 2028. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
Breakeven Date Change • May 21No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$28.8m in 2027. New consensus forecast suggests the company will make a loss of NZ$15.4m in 2027.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.62m in 2023. New consensus forecast suggests the company will make a loss of NZ$1.85m in 2024.
Breakeven Date Change • Sep 28Forecast to breakeven in 2023The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$4.58m in 2023. Average annual earnings growth of 94% is required to achieve expected profit on schedule.
お知らせ • Jul 02Pacific Edge Limited, Annual General Meeting, Aug 20, 2026Pacific Edge Limited, Annual General Meeting, Aug 20, 2026. Location: auckland New Zealand
Reported Earnings • May 26Full year 2026 earnings released: NZ$38.00 loss per share (vs NZ$0.037 loss in FY 2025)Full year 2026 results: NZ$38.00 loss per share (further deteriorated from NZ$0.037 loss in FY 2025). Revenue: NZ$13.6m (down 40% from FY 2025). Net loss: NZ$35.8m (loss widened 20% from FY 2025). Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 4.1% growth forecast for the Biotechs industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 179 percentage points per year, which is a significant difference in performance.
New Risk • May 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 44% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (44% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (NZ$18m net loss in 2 years).
お知らせ • May 15Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 25.4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 149,411,765 Price\Range: NZD 0.17 Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2026 Results on May 25, 2026Pacific Edge Limited announced that they will report fiscal year 2026 results at 10:00 AM, IDLE - International Date Line on May 25, 2026
Breakeven Date Change • May 12Forecast to breakeven in 2028The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 8.0% per year to 2027. The company is expected to make a profit of NZ$6.80m in 2028. Average annual earnings growth of 55% is required to achieve expected profit on schedule.
New Risk • Mar 31New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$145.8m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Share price has been volatile over the past 3 months (17% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$145.8m market cap, or US$99.9m).
New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding).
Reported Earnings • Nov 27First half 2026 earnings released: NZ$0.022 loss per share (vs NZ$0.018 loss in 1H 2025)First half 2026 results: NZ$0.022 loss per share (further deteriorated from NZ$0.018 loss in 1H 2025). Revenue: NZ$6.84m (down 40% from 1H 2025). Net loss: NZ$19.1m (loss widened 32% from 1H 2025). Revenue is expected to decline by 2.8% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Australia are expected to grow by 7.6%. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
New Risk • Nov 26New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -NZ$32m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-NZ$32m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$16m net loss in 2 years). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$147.4m market cap, or US$95.3m).
New Risk • Nov 10New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$150.9m (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$4.9m net loss in 3 years). Share price has been volatile over the past 3 months (15% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$150.9m market cap, or US$98.6m).
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2026 Results on Nov 25, 2025Pacific Edge Limited announced that they will report first half, 2026 results on Nov 25, 2025
New Risk • Aug 25New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (20% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$11m net loss in 3 years). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (AU$122.8m market cap, or US$79.7m).
お知らせ • Jun 16Pacific Edge Limited, Annual General Meeting, Aug 06, 2025Pacific Edge Limited, Annual General Meeting, Aug 06, 2025. Location: auckland New Zealand
お知らせ • Jun 03Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million.Pacific Edge Limited has completed a Follow-on Equity Offering in the amount of NZD 16 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 150,000,000 Price\Range: NZD 0.1 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 10,000,000 Price\Range: NZD 0.1 Transaction Features: Subsequent Direct Listing
Reported Earnings • Jun 01Full year 2025 earnings released: NZ$0.037 loss per share (vs NZ$0.036 loss in FY 2024)Full year 2025 results: NZ$0.037 loss per share (further deteriorated from NZ$0.036 loss in FY 2024). Revenue: NZ$24.7m (down 2.2% from FY 2024). Net loss: NZ$29.9m (loss widened 1.4% from FY 2024). Revenue is expected to decline by 25% p.a. on average during the next 2 years, while revenues in the Biotechs industry in Australia are expected to grow by 8.6%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
お知らせ • May 31Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million.Pacific Edge Limited has filed a Follow-on Equity Offering in the amount of NZD 5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: NZD 0.1
お知らせ • May 30Pacific Edge Limited has filed a Follow-on Equity Offering.Pacific Edge Limited has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: Subsequent Direct Listing
お知らせ • May 12Pacific Edge Limited to Report Fiscal Year 2025 Results on May 30, 2025Pacific Edge Limited announced that they will report fiscal year 2025 results at 4:45 PM, IDLE - International Date Line on May 30, 2025
New Risk • Jan 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: NZ$29m Forecast net loss in 2 years: NZ$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (NZ$23m net loss in 2 years). Market cap is less than US$100m (AU$44.0m market cap, or US$27.0m).
Reported Earnings • Nov 30First half 2025 earnings released: NZ$0.018 loss per share (vs NZ$0.019 loss in 1H 2024)First half 2025 results: NZ$0.018 loss per share (improved from NZ$0.019 loss in 1H 2024). Revenue: NZ$11.3m (down 19% from 1H 2024). Net loss: NZ$14.5m (loss narrowed 4.9% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 06Pacific Edge Limited to Report First Half, 2025 Results on Nov 26, 2024Pacific Edge Limited announced that they will report first half, 2025 results on Nov 26, 2024
Reported Earnings • May 21Full year 2024 earnings released: NZ$0.036 loss per share (vs NZ$0.033 loss in FY 2023)Full year 2024 results: NZ$0.036 loss per share (further deteriorated from NZ$0.033 loss in FY 2023). Revenue: NZ$28.7m (up 36% from FY 2023). Net loss: NZ$29.5m (loss widened 9.5% from FY 2023).
Breakeven Date Change • May 21No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$28.8m in 2027. New consensus forecast suggests the company will make a loss of NZ$15.4m in 2027.
お知らせ • May 07Pacific Edge Limited, Annual General Meeting, Sep 24, 2024Pacific Edge Limited, Annual General Meeting, Sep 24, 2024.
お知らせ • May 01Pacific Edge Limited to Report Fiscal Year 2024 Results on May 21, 2024Pacific Edge Limited announced that they will report fiscal year 2024 results at 10:00 AM, NZST - New Zealand Standard on May 21, 2024
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Anna Stove was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Mar 14Pacific Edge Limited Announces Board ChangesPacific Edge Limited announced the retirement of Chair Chris Gallaher and Non-Executive Director Mark Green. Mr. Gallaher, who joined the Pacific Edge Board in July 2016, has resolved to reduce his governance commitments, and has indicated his intention to retire from the Board following the appointment of a successor and a structured handover at the end of this year. Meanwhile, with his family having made new commitments offshore, Mr. Green has notified the Board he does not intend to seek re-election at the company's next Annual Shareholders Meeting in September. Mr. Green joined the Pacific Edge Board in May 2021. The Board's Nomination Committee has commenced a process to appoint a new Chair and consider the recruitment of new Independent Directors.
Reported Earnings • Nov 24First half 2024 earnings released: NZ$0.019 loss per share (vs NZ$0.013 loss in 1H 2023)First half 2024 results: NZ$0.019 loss per share (further deteriorated from NZ$0.013 loss in 1H 2023). Revenue: NZ$14.0m (up 47% from 1H 2023). Net loss: NZ$15.3m (loss widened 44% from 1H 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Biotechs industry in Australia.
お知らせ • Oct 19Pacific Edge Limited to Report First Half, 2024 Results on Nov 23, 2023Pacific Edge Limited announced that they will report first half, 2024 results on Nov 23, 2023
Recent Insider Transactions • Sep 21Independent Non-Executive Director recently bought AU$2.8m worth of stockOn the 15th of September, Anatole G. Masfen bought around 9m shares on-market at roughly AU$0.31 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$2.9m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Aug 04Key Executive recently bought AU$50k worth of stockOn the 2nd of August, Chris Gallaher bought around 398k shares on-market at roughly AU$0.13 per share. This transaction amounted to 66% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Chris' only on-market trade for the last 12 months.
お知らせ • Jun 09Pacific Edge Limited Announces Medicare Coverage of Cxbladder Tests in the US Market is Expected to Cease from 17 July 2023Pacific Edge announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. This development follows the finalization of a Local Coverage Determination (LCD) (L39365) by Novitas, the Medicare Administrative Contractor (MAC) with jurisdiction for Pacific Edge's laboratory in Hershey Pennsylvania. The finalized LCD, which includes Cxbladder and tests provided by other companies, specifically notes the Cxbladder tests Triage, Detect, Monitor, Resolve and Detect+ as `not considered medically reasonable and necessary', the threshold required for coverage under the US Social Security Act. A number of other companies are also affected by the LCD. Over the coming days Pacific Edge will seek to explore all available legal options (including a potential appeal) with US-based lawyers, the key opinion leaders among customers, partners at The Coalition for 21st Century Medicine, and other impacted companies. Pacific Edge is currently unable to fully determine the impact of the new LCD on test volumes in the US market for the 2024 financial year. For the immediate future, the company will continue to promote Cxbladder and process all tests ordered by US clinicians whilst it further considers its strategy and future options. The company believes that in the short term it is prudent to continue to support Cxbladder as it determines the best path forward, but the approach will be accompanied by cost containment initiatives including, but not limited to an immediate hiring freeze and a halt on discretionary spending and new capital expenditure. In light of this new LCD, management and the Board at Pacific Edge are reviewing the scenario planning commenced last year to determine a strategic path forward that potentially includes: a) legal challenges or appeals, b) seeking to regain coverage through Novitas, c) seeking to be awarded coverage through an alternative MAC, d) alternative billing practices that would increase patient responsibility and e) remaining open to other strategic alternatives. Which of these the company adopts, will be determined by considering a number of factors including the potential impact on revenue, expenditure and cash reserves, the time and resources required to regain coverage, shareholder value implications, and the expected likelihood of success.
New Risk • Jun 08New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: AU$80.1m (US$53.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (NZ$3.9m net loss in 3 years). Market cap is less than US$100m (AU$80.1m market cap, or US$53.4m).
Reported Earnings • May 26Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: NZ$0.033 loss per share (further deteriorated from NZ$0.026 loss in FY 2022). Revenue: NZ$23.8m (up 81% from FY 2022). Net loss: NZ$27.0m (loss widened 36% from FY 2022). Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates by 10%. Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Biotechs industry in Australia.
Reported Earnings • Nov 28First half 2023 earnings released: NZ$0.013 loss per share (vs NZ$0.012 loss in 1H 2022)First half 2023 results: NZ$0.013 loss per share (further deteriorated from NZ$0.012 loss in 1H 2022). Revenue: NZ$9.47m (up 55% from 1H 2022). Net loss: NZ$10.6m (loss widened 18% from 1H 2022). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Australia.
Reported Earnings • May 27Full year 2022 earnings released: NZ$0.026 loss per share (vs NZ$0.02 loss in FY 2021)Full year 2022 results: NZ$0.026 loss per share (down from NZ$0.02 loss in FY 2021). Revenue: NZ$13.7m (up 53% from FY 2021). Net loss: NZ$19.8m (loss widened 39% from FY 2021). Over the next year, revenue is forecast to grow 60%, compared to a 71% growth forecast for the pharmaceuticals industry in Australia.
Buying Opportunity • May 27Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be AU$0.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 93% over the last year. Earnings per share has grown by 11%. For the next 3 years, revenue is forecast to grow by 46% per annum. Earnings is forecast to decline by 3.7% per annum over the same time period.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Sarah Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Jan 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Independent Director Sarah Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 26First half 2022 earnings: EPS in line with analyst expectations despite revenue beatFirst half 2022 results: NZ$0.012 loss per share (down from NZ$0.01 loss in 1H 2021). Revenue: NZ$6.13m (up 71% from 1H 2021). Net loss: NZ$8.99m (loss widened 27% from 1H 2021). Revenue exceeded analyst estimates by 3.6%. Over the next year, revenue is forecast to grow 85%, compared to a 176% growth forecast for the industry in Australia.
Breakeven Date Change • Nov 24No longer forecast to breakevenThe 2 analysts covering Pacific Edge no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of NZ$3.62m in 2023. New consensus forecast suggests the company will make a loss of NZ$1.85m in 2024.
Breakeven Date Change • Sep 28Forecast to breakeven in 2023The 2 analysts covering Pacific Edge expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of NZ$4.58m in 2023. Average annual earnings growth of 94% is required to achieve expected profit on schedule.